The Perils of Single‐Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next‐Generation Sequencing
Casasanta N, Stark E, McHenry A, Biagi T, Kaltman R. The Perils of Single‐Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next‐Generation Sequencing. The Oncologist 2018, 23: 393-396. PMID: 29445031, PMCID: PMC5896713, DOI: 10.1634/theoncologist.2017-0372.Peer-Reviewed Original ResearchMeSH KeywordsAdultAtaxia Telangiectasia Mutated ProteinsBiomarkers, TumorFemaleGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingGenotypeHereditary Breast and Ovarian Cancer SyndromeHigh-Throughput Nucleotide SequencingHumansMutationNeoplasm ProteinsPedigreeConceptsHereditary cancer syndromesCancer syndromesGenetic testingExpanded panel testingOvarian cancer syndromeNational Comprehensive Cancer Network criteriaFemale breast cancerOptimal management of cancer patientsPanel testingClinical genetic testingHereditary genetic syndromesManagement of cancer patientsHereditary breastGenetic riskFamily historyGenetic counselingCell cycle checkpoint arrestCounseling patientsDouble-strand DNA break repairEra of next-generation sequencingBreast cancerNetwork criteriaClinical managementClinical significanceFamily members